Patients having sentinel node (SN) biopsy for melanoma the day after lymphoscintigraphy using Tc99m-nanocolloid are reported to have worse survival outcome than that of patients having lymphoscintigraphy and SN biopsy on the same day.
Publications
Optimising prediction of early metastasis-free survival in uveal melanoma using a four-category model incorporating gene expression profile and tumour size
Since largest basal diameter (LBD) seems to have independent prognostic worth in uveal melanoma (UM), this topic is further studied herein among all patients undergoing plaque brachytherapy or enucleation for UM involving the choroid and/or ciliary body between 2012 and 2019.
Association of histologic regression with a favorable outcome in patients with stage 1 and stage 2 cutaneous melanoma
In patients with primary cutaneous melanoma, this study was undertaken to investigate if histologically confirmed regression was correlated with better or worse survival.
Tebentafusp Named FDA Breakthrough Therapy for Advanced Eye Cancer
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Immunocore‘s tebentafusp (IMCgp100) for HLA-A2 positive, inoperable, or advanced uveal melanoma — a common and difficult-to-treat form of eye cancer — the company announced in a press release.